Phase 3 Readout~month
Phase 3 Topline: An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With
- Company
- ARDELYX, INC. (ARDX)
- Drug
- tenapanor
Other upcoming events for ARDX
Phase 3 ReadoutPhase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi
Phase 3 ReadoutPhase 3 Topline: A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and
Phase 3 ReadoutPhase 3 Topline: An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With
Patent ExpiryPatent/Exclusivity Expiry: XPHOZAH
Patent ExpiryPatent/Exclusivity Expiry: IBSRELA
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.